Monitor for additional insider selling or changes in trading plan disclosures; current activity is within normal ranges for a company of this size and does not signal material concern.
MDGL drugs
MDGL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $425.85entry
- T+1 · 9mo ago +2.10%α +1.40% · $434.80
- T+5 · 8mo ago +1.63%α +2.09% · $432.78
- T+20 · 8mo ago +22.92%α +27.33% · $523.47
- T+60 · 6mo ago +21.16%α +10.24% · $515.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Madrigal Pharmaceuticals insiders conducted open-market sales totaling $717K in the past week, including CFO Mardi Dier selling $505K of shares. A separate non-cash award of shares to the Chief Medical Officer does not represent economic activity. The sales amount to a small fraction of the company's $10.1B market cap and align with routine pre-arranged trading plans.
Key Financial Metrics
Key Facts
- CFO Mardi Dier sold 1,183 shares for $505,389 in an open-market transaction.
- Director Rebecca Taub sold 491 shares for $212,083, also in an open-market sale.
- Chief Medical Officer David Soergel was granted 4,374 shares at $0 value, a non-cash equity award.
- Total open-market sale value: $717,479.
- Cluster represents approximately 0.007% of the company's $10.1B market cap.
Financial Impact
$717K in net insider selling over 7 days
Risk Factors
- Perception risk if selling continues or accelerates ahead of key events like earnings or regulatory decisions.
- Concentration risk in executive decision-making given limited number of active insiders trading.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (3 trades, 7d window) | cluster-MDGL-1772838475323 |
Track record
18 reports on MDGL
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +10.26% at T+20 after the Jul 30, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 3, 202613d ago 8-K Bullish 7/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
- Aug 12, 202613w ago 8-K Neutral 3/10 Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers